PR Emerges as the Primary Source for Journalists in High-Pressure Newsrooms
Cision's 2026 State of the Media Report reveals 66% of journalists rely…
WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure
GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech…
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
MINNEAPOLIS, May 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a…
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability…
SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD
TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a…
Silver Lake and Nomura Securities Form a Strategic Partnership to Establish a Primary Trading Account and Co-Create a New Blueprint for Japans Capital Markets
Menlo Park, California, March 06, 2026 (GLOBE NEWSWIRE) -- We are pleased…
Star Health Launches 32 Arogya Seva Kendras; to Provide Primary Healthcare Access to over a Million Lives
First Arogya Seva Kendra inaugurated in Egmore, Chennai; Tamil Nadu rollout includes Nagercoil,…
Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock
December 04, 2025 22:05 ET | Source: Symbotic Inc. WILMINGTON, Mass., Dec.…
